8-K: AN2 Therapeutics Reports Q1 2024 Financials and Provides Clinical Trial Update

AN2 Therapeutics announced its first quarter 2024 financial results and provided an update on its Phase 2/3 clinical trial for epetraborole, including a planned topline data release in August 2024.

Summary

• AN2 Therapeutics reported a net loss of $16.6 million for the first quarter of 2024, compared to a $15.3 million loss in the same period of 2023.
• Research and development expenses increased to $14.7 million in Q1 2024 from $12.0 million in Q1 2023, driven by higher clinical trial costs.
• General and administrative expenses decreased to $3.6 million in Q1 2024 from $4.1 million in Q1 2023 due to lower professional service and insurance costs.
• The company's cash, cash equivalents, and investments totaled $118.1 million as of March 31, 2024.
• AN2 Therapeutics expects to report topline data from the Phase 2 portion of its EBO-301 trial in August 2024.
• The company voluntarily paused enrollment in the Phase 3 portion of the trial in February 2024 due to potentially lower than expected efficacy observed in blinded Phase 2 data.
• The decision to resume Phase 3 enrollment will be made after reviewing the unblinded Phase 2 data and discussions with the FDA.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the pause in Phase 3 enrollment and the indication of lower than expected efficacy in Phase 2 data. While the company has a strong cash position, the clinical trial setback is a significant concern.

Positives

• The company has a strong cash position of $118.1 million, providing financial stability.
• Other income increased to $1.7 million due to higher interest and investment income.
• The company is actively progressing its clinical trial for epetraborole, with topline Phase 2 data expected soon.
• The company is continuing to dose the 97 patients already enrolled in the Phase 3 trial.

Negatives

• The company experienced a net loss of $16.6 million in Q1 2024.
• Research and development expenses increased significantly, impacting profitability.
• The voluntary pause of Phase 3 enrollment indicates potential concerns about the efficacy of epetraborole.
• The Phase 2 data showed potentially lower than expected efficacy.

Risks

• The company's ability to resume Phase 3 enrollment is uncertain and depends on Phase 2 data and FDA feedback.
• There is a risk that the Phase 2 data may not be positive, which could impact the future of epetraborole.
• The company may need additional capital to achieve its goals.
• The clinical trial results may differ from preclinical or early clinical results.
• There is a risk of adverse events or toxicities associated with the product candidate.

Future Outlook

The company anticipates reporting topline data from the Phase 2 portion of the EBO-301 trial in August 2024, which will be critical in determining the path forward for epetraborole. The continuation of Phase 3 enrollment is contingent on the Phase 2 results and discussions with the FDA.

Management Comments

• Eric Easom, Co-Founder, President and Chief Executive Officer, stated that the patients enrolled in EBO-301 are highly refractory with limited to no treatment options.
• Eric Easom hopes to see data demonstrating that epetraborole on top of background therapy will show benefit in these toughest to treat patients.

Industry Context

AN2 Therapeutics is focused on developing treatments for rare, chronic, and serious infectious diseases, specifically targeting NTM lung disease. This is an area of high unmet need, and the company's progress is being closely watched by investors and the medical community. The company is competing with other companies developing treatments for NTM, including those with FDA approved drugs such as Arikayce.

Comparison to Industry Standards

• The company's R&D spending of $14.7 million in Q1 2024 is typical for a clinical-stage biotech company focused on a Phase 2/3 trial.
• The cash position of $118.1 million is relatively strong for a company of this size, providing a runway for further development.
• The voluntary pause in Phase 3 enrollment is not uncommon in clinical trials, especially when early data suggests potential issues with efficacy.
• Companies such as Insmed, which markets Arikayce, are direct competitors in the NTM space, and AN2's results will be compared against the efficacy and safety profiles of existing treatments.

Stakeholder Impact

• Shareholders may be concerned about the pause in Phase 3 enrollment and the potential implications for the company's future.
• Employees may be affected by any changes in the company's strategy or clinical trial plans.
• Patients with TR-MAC are awaiting the results of the clinical trial, as there are limited treatment options available.

Next Steps

• The company will analyze the unblinded Phase 2 data from the EBO-301 trial.
• The company will have discussions with the FDA regarding the Phase 2 data and the path forward.
• The company will determine whether to resume enrollment in the Phase 3 portion of the EBO-301 trial.
• The company will continue to dose the 97 patients already enrolled in the Phase 3 trial.

Key Dates

Keywords

epetraborole, Mycobacterium avium Complex, TR-MAC, clinical trial, Phase 2, Phase 3, biopharmaceutical, infectious diseases, FDA, research and development